**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript NO: 27306**

**Manuscript Type: Diagnostic Advances**

**Intra-cardiac distribution of late gadolinium enhancement in cardiac sarcoidosis and dilated cardiomyopathy**

Sano M *et al.* LE in cardiac sarcoidosis and DCM

**Makoto Sano, Hiroshi Satoh, Kenichiro Suwa, Masao Saotome, Tsuyoshi Urushida, Hideki Katoh, Hideharu Hayashi, Takeji Saitoh**

**Makoto Sano, Hiroshi Satoh, Kenichiro Suwa, Masao Saotome, Tsuyoshi Urushida, Hideki Katoh, Hideharu Hayashi,** Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Takeji Saitoh,** Department of Emergency Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Author contributions:** Sano M, Suwa K and Saitoh T designed and performed the research; Satoh H wrote the manuscript; Saotome M, Urushida T, Katoh H and Hayashi H reviewed the manuscript.

**Conflict-of-interest** **statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Hiroshi Satoh, MD, PhD,** Division of Cardiology, Internal Medicine III,Hamamatsu University School of Medicine,1-20-1 Handayama, Higashi-ward, Hamamatsu 431-3192, Japan. [satoh36@hama-med.ac.jp](mailto:satoh36@hama-med.ac.jp)

**Telephone:** +81-53-4352267

**Fax:** +81-53-4342910

**Received:** May 23, 2016

**Peer-review started:** May 23, 2016

**First decision:** June 17, 2016

**Revised:** July 12, 2016

**Accepted:** July 29, 2016

**Article in press:**

**Published online:**

**Abstract**

Cardiac involvement of sarcoid lesions is diagnosed by myocardial biopsy which is frequently false-negative, and patients with cardiac sarcoidosis (CS) who have impaired left ventricular (LV) systolic function are sometimes diagnosed with dilated cardiomyopathy (DCM). Late gadolinium enhancement (LE) in magnetic resonance imaging is now a critical finding in diagnosing CS, and the novel Japanese guideline considers myocardial LE to be a major criterion of CS. This article describes the value of LE in patients with CS who have impaired LV systolic function, particularly the diagnostic and clinical significance of LE distribution in comparison with DCM. LE existed at all LV segments and myocardial layers in patients with CS, whereas it was localized predominantly in the midwall of basal to mid septum in those with DCM. Transmural (nodular), circumferential, and subepicardial and subendocardial LE distribution were highly specific in patients with CS, whereas the prevalence of striated midwall LE were high both in patients with CS and with DCM. Since sarcoidosis patients with LE have higher incidences of heart failure symptoms, ventricular tachyarrhythmia and sudden cardiac death, the analyses of extent and distribution of LE are crucial in early diagnosis and therapeutic approach for patients with CS.

**Key words:** Magnetic resonance imaging; Late gadolinium enhancement; Sarcoidosis; Dilated cardiomyopathy; Diagnosis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Late gadolinium enhancement (LE) in magnetic resonance imaging is a critical finding in the diagnosis of cardiac sarcoidosis (CS), but it is also observed in dilated cardiomyopathy (DCM). We review the significance of LE distribution in comparison with DCM. LE distributed into all ventricular segments and myocardial layers in CS, whereas it was localized predominantly in the midwall of ventricular septum in DCM. Transmural, circumferential, and subepicardial and subendocardial LE were highly specific in CS. Since patients with LE have more adverse cardiac events, the analyses of extent and distribution of LE are crucial for diagnosis and management of CS.

Sano M, Satoh H, Suwa K, Saotome M, Urushida T, Katoh H, Hayashi H, Saitoh T. Intra-cardiac distribution of late gadolinium enhancement in cardiac sarcoidosis and dilated cardiomyopathy. *World J Cardiol* 2016; In press

**INTRODUCTION**

Sarcoidosis is a multi-organ granulomatous disorder of undetermined aetiology. Cardiac involvement is identified clinically only in few percentage (%) of patients with systemic sarcoidosis, while post-mortem investigations have found myocardial lesions in around 60%[1]. Necropsies exhibited that cardiac involvement was mostly non-transmural and lesions were located predominantly in the basal left ventricle (LV) and subepicardial myocardium[2,3]. Patients with cardiac sarcoidosis (CS) have a poor prognosis due to congestive heart failure with impaired LV function, and sudden cardiac death associated with lethal ventricular tachycardia (VT) or conduction disturbance[4].

Although endomyocardial biopsy has been the gold standard in diagnosing CS, it has limited sensitivity and certain procedural risks[5]. Actually, the results of endomyocardial biopsy were frequently false negative because of the patchy distribution of the lesions. Therefore, patients with cardiac involvement of systemic sarcoidosis (sCS) and with isolated CS (iCS) are not always positive for endomyocardial biopsy. As a result, a certain part of patients may be diagnosed with normal or dilated cardiomyopathy (DCM), and do not receive immunosuppressive therapies. Since a corticosteroid therapy can improve long-term prognosis of CS[6,7], an earlier diagnosis of CS with non-invasive cardiac imaging is clinically significant.

The recent development of various imaging modalities including magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose-positron emission computed tomography (FDG-PET) has enabled more precise diagnosis of CS. The LV wall in most patients with CS has late gadolinium enhancement (LE) in MRI[5,8-10], and the novel guideline of Japanese Ministry of Health and Welfare (JMH) considers the presence of LE to be a major criterion in CS (Table 1)[11]. However, LE is non-specific and frequently observed in other cardiomyopathies including DCM.

We have been investigating the patterns of LE distribution in various cardiomyopathies and trying to confirm the values for differential diagnosis, clinical features, and prognosis[12-18]. Here we describes the value of LE in patients with CS, particularly the diagnostic and clinical significance of LE distribution in comparison with DCM.

**LE DISTRIBUTION IN CS AND DIFFERENTIAL DIAGNOSIS FROM DCM**

***Patient characteristics***

We initially enrolled 21 patients with CS who had LE in the myocardium between 2003 and 2015. Among them, the intra-cardiac and intra-mural distribution of LE were analyzed in 14 (67%) patients (13 sCS and 1 iCS) who showed reduced LV ejection fraction (LVEF: < 50%). The clinical characteristics and LE features were compared with 30 patients with DCM who were diagnosed by the World Health Organization/International Society and Federation of Cardiology definition of cardiomyopathies[19]. The present study was performed in accordance with the Declaration of Helsinki and the protocol was approved by an institutional review board. All study participants provided informed consent.

Patients with CS included more female patients and were younger, but there were no differences in symptoms, ECG findings and medications excluding corticosteroids (Table 2). Patients with CS had less decreased LVEF and smaller LV end-systolic volume index, while LV end-diastolic volume index and LV mass index did not differ from those in DCM. The LV segment number with LE was also greater in patients with CS. Figure 1 shows LE-MRI images (left) and corresponding FDG-PET (middle) and 99mTc-sestamibi single photon emission computed tomography (SPECT: right) in a 61-year-old patient with sCS. LE-MRI exhibits diffuse LE in the subepicardium (RV side) and subendocardium (LV side) of basal to apical ventricular septum and patchy LE in the midwall of posterior LV (white arrows). FDG-PET demonstrates focal uptake in basal and apical ventricular septum and posterior LV wall (black arrows). 99mTc-sestamibi SPECTshows a defect only in ventricular septum (black arrows).

***Intra-LV and intra-mural LE distribution***

The intra-LV LE distribution was analyzed using the 17-segments model[16]. Next, we visually divided the intra-mural LE distribution into subepicardial, midwall and subendocardial distribution. Then, the extent of LE in each segment was determined with a five-point scoring system (0 = no LE, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%-100% of transmural extent of LE). The segment with score 4 was defined as “transmural” distribution[16]. LE in patients with CS existed predominantly in the basal and mid septum, but also distributed throughout LV segments. While in patients with DCM, LE was localized mostly in the basal and mid septum[13,16]. In addition, LE distributed across all the myocardial layers in patients with CS, but was predominantly localized at the midwall in those with DCM (Figure 2). The averaged LE score in each LV segment was significantly higher in CS than that in DCM [0.95 ± 0.67 *vs* 0.42 ± 0.43, mean ± standard deviation (SD), *P* < 0.05].

***Typical LE distribution profiles***

Previous reports have also shown that transmural (nodular) distribution, circumferential subepicardial distribution, and subepicardial and subendocardial distribution (with spared midwall) are highly characteristic in CS, whereas striated distribution in midwall is typical in DCM (Figure 3A)[5,10]. In our analysis, transmural (nodular), circumferential, and subepicardial and subendocardial LE distribution were highly specific in patients with CS, although the prevalence of those distribution patterns was low. In contrast, the prevalence of striated midwall LE distribution was high in both groups, but the specificity was low (Figure 3B and Table 3).

**DISCUSSION**

We initially demonstrated typical findings of various cardiac imaging in a patient with CS. Many reports have exhibited the correlations among LE-MRI, SPECT and FDG-PET in the evaluation of CS. The intra-mural extent of LE was quite concordant with perfusion defects in 201Tl- or 99mTc-sestamibi-SPECT[9,13]. On the other hand, FDG-PET exhibits focal or focal on diffuse type of hot spots in CS[20-22]. While LE and defects in SPECT reflect irreversible fibro-granulomatous replacement, the hot spots in T2-weighted black-blood imaging (T2WBB), 67Ga-SPECT and FDG-PET express active inflammatory change. The hot spots can be targeted for an endomyocardial biopsy if tissue diagnosis is required, and be adopted for an evaluation of corticosteroid therapy[21,23]. Since FDG-PET can give higher sensitivity and specificity than SPECT, we recommend the combination of LE-MRI and FDG-PET for assessing CS[20,21]. LE sometimes overlaps with hot spots in FDG-PET or T2WBB according to the disease progression or recurrence. Thus, it is important to carefully interpret findings in LE-MRI and other imaging modalities[24].

***LE distributions in CS***

Managing patients with reduced LV contraction who are suspected CS without histologic manifestation is a critical issue, since these cases may be diagnosed with DCM, and do not receive corticosteroid therapy[25]. Oppositely, the inclusion of the presence of LE in the novel JMH guideline (Table 1) may cause an increase in false positive patients. Although FDG-PET can be an additional tool for diagnosing CS, it is not always available in all hospitals and patients. Therefore, more detailed analyses of LE-MRI are required to differentiate CS from DCM.

Many previous studies have clarified the characteristic LE distribution in CS (Table 4). In general, LE in CS is polymorphic and heterogeneous; a classic pattern of midwall or subepicardial LE can be seen, but subendocardial or transmural LE as in patients with ischemic cardiomyopathy is also possible. LE may correspond to the location of wall thinning, wall motion abnormalities and myocardial edema[5,8,10,13,25-30]. Tezuka *et al*[25] reported that there was no difference in LE distribution between sCS and iCS.

In our analysis, transmural (nodular), circumferential, and subepicardial and subendocardial LE distribution were highly specific in patients with CS, although the prevalence of those distribution patterns was low. In contrast, the prevalence of striated midwall LE distribution was high in both groups, but the specificity was low. Although the mechanisms of these types of LE distribution remain unknown, more aggressive examination for CS such as serological tests, 67Ga-SPECT and FDG-PET should be considered, when patients with reduced LVEF showed diffuse and characteristic features of LE distribution.

***Clinical implications of LE***

In general, LE in patients with cardiomyopathies correlates with all-cause mortality, heart failure hospitalization, and sudden cardiac death. Thus, detection of LE by LE-MRI has excellent prognostic significance and may help guide risk stratification and management in patients with various cardiomyopathies[17,31].

In sarcoidosis, previous reports showed that patients with LE in myocardium had high prevalence of heart failure symptoms, ECG abnormalities and lethal arrhythmias[5,28]. There are significant correlations between LE burden, and LV volume and function[5,8,10,27]. Regions of granulomatous infiltration evolving into scar tissue serve as substrates for re-entrant tachyarrhythmia[32,33]. Murtah *et al*[34] exhibited that increased LE burden and right ventricular dysfunction can identify patients at highest risk of sudden cardiac death and VT. The efficacies of implantable cardioverter defibrillator (ICD) and catheter ablation were also reported for preventing sudden cardiac death and VT storm[35,36]. Therefore, not only the presence of LE, but also the LE burden and distribution should be considered for the risk stratification and therapeutic approach for CS. Although the smaller LE burden or non-specific scarring may be associated with a benign outcome[37], patients with LE should be carefully followed up, even when they had preserved LV function because of certain risks for sudden cardiac death and VT.

Tezuka *et al*[25] mentioned that the clinical features and prognosis did not differ between patients with sCS and iCS, whereas Kandolin *et al*[38] showed poorer outcomes in patients with iCS. The total segments with LE may correlate with the duration of extra-CS[27]. LE in CS mostly reflects irreversible myocardial scarring, and previous reports failed to show a decrease in LE volume after corticosteroid therapy[5,8,29]. The serial FDG-PET imaging is valuable to evaluate the effect of corticosteroid therapy for cardiac and systemic sarcoid lesions[21,39].

***Limitations***

Initially, MRI is not always available in all hospitals and patients, and has a problem of cost. Patients with pulmonary congestion cannot tolerate long data acquisition time of MRI. MRI has been prohibited in patients who have had device implantation. Therefore, patients who required urgent pacemaker or ICD implantation because of atrioventricular blocks or VT were excluded from the analyses of MRI. MR conditional pacemakers can be implanted in patients who may need MRI after device implantation[40,41]. Gadolinium cannot be injected to patients with chronic renal failure, because there is a risk of nephrogenic systemic fibrosis. Finally, different determination thresholds (> 2 SD to > 5 SD) and difficult quantification of LE are also limitations.

**CONCLUSION**

Although LE in myocardium has become a major criterion in the novel JMH guideline for CS, the present article suggests that more diffuse and characteristic patterns of LE distribution (in combination with abnormal wall motion and morphology) may be helpful for differentiating CS from DCM in patients with reduced LVEF. Future large and longitudinal follow-up studies are necessary to define characteristic patterns of LE distribution in CS as well as those prognostic values.

**REFERENCES**

1 **Hunninghake GW**, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. *Sarcoidosis Vasc Diffuse Lung Dis* 1999; **16**: 149-173 [PMID: 10560120]

2 **Roberts WC**, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). *Am J Med* 1977; **63**: 86-108 [PMID: 327806 DOI: 10.1016/0002-9343(77)90121-8]

3 **Silverman KJ**, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. *Circulation* 1978; **58**: 1204-1211 [PMID: 709777 DOI: 10.1161/01.CIR.58.6.1204]

4 **Sharma OP**, Maheshwari A, Thaker K. Myocardial sarcoidosis. *Chest* 1993; **103**: 253-258 [PMID: 8417889 DOI: 10.1378/chest.103.1.253]

5 **Patel MR**, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. *Circulation* 2009; **120**: 1969-1977 [PMID: 19884472 DOI: 10.1161/CIRCULATIONAHA.109.851352]

6 **Yazaki Y**, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. *Am J Cardiol* 2001; **88**: 1006-1010 [PMID: 11703997 DOI: 10.1016/S0002-9149(01)01978-6]

7 **Nagai T**, Nagano N, Sugano Y, Asaumi Y, Aiba T, Kanzaki H, Kusano K, Noguchi T, Yasuda S, Ogawa H, Anzai T. Effect of Corticosteroid Therapy on Long-Term Clinical Outcome and Left Ventricular Function in Patients With Cardiac Sarcoidosis. *Circ J* 2015; **79**: 1593-1600 [PMID: 25877828 DOI: 10.1253/circj.CJ-14-1275]

8 **Smedema JP**, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP, Crijns HJ. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. *Chest* 2005; **128**: 1629-1637 [PMID: 16162768 DOI: 10.1378/chest.128.3.1629]

9 **Tadamura E**, Yamamuro M, Kubo S, Kanao S, Saga T, Harada M, Ohba M, Hosokawa R, Kimura T, Kita T, Togashi K. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. *AJR Am J Roentgenol* 2005; **185**: 110-115 [PMID: 15972409 DOI: 10.2214/ajr.185.1.01850110]

10 **Ichinose A**, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, Takahashi S. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. *AJR Am J Roentgenol* 2008; **191**: 862-869 [PMID: 18716120 DOI: 10.2214/AJR.07.3089]

11 **Shijubo N**, Yamaguchi T. Diagnosis Criteria and Classification of Disease Severity for Sarcoidosis in Japan (in Japanese). *Japan Society of Sarcoidosis and other Granulomatous Disorders* 2015; **35**: 3-8 [DOI: 10.7878/jjsogd.35.3]

12 **Matoh F**, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. *J Card Fail* 2007; **13**: 372-379 [PMID: 17602984 DOI: 10.1016/j.cardfail.2007.06.139]

13 **Matoh F**, Satoh H, Shiraki K, Odagiri K, Saitoh T, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. *J Cardiol* 2008; **51**: 179-188 [PMID: 18522793 DOI: 10.1016/j.jjcc.2008.03.002]

14 **Satoh H**, Matoh F, Shiraki K, Saitoh T, Odagiri K, Saotome M, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H. Delayed enhancement on cardiac magnetic resonance and clinical, morphological, and electrocardiographical features in hypertrophic cardiomyopathy. *J Card Fail* 2009; **15**: 419-427 [PMID: 19477402 DOI: 10.1016/j.cardfail.2008.11.014]

15 **Shiraki K**, Satoh H, Saitoh T, Saotome M, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H. Comparison of global and regional abnormalities in 99mTc-sestamibi and cardiac magnetic resonance imaging in dilated cardiomyopathy. *J Card Fail* 2010; **16**: 641-648 [PMID: 20670843 DOI: 10.1016/j.cardfail.2010.03.004]

16 **Machii M**, Satoh H, Shiraki K, Saotome M, Urushida T, Katoh H, Takehara Y, Sakahara H, Ohtani H, Wakabayashi Y, Ukigai H, Tawarahara K, Hayashi H. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. *Magn Reson Imaging* 2014; **32**: 118-124 [PMID: 24315973 10.1016/j.mri.2013.10.011]

17 **Satoh H**, Sano M, Suwa K, Saitoh T, Nobuhara M, Saotome M, Urushida T, Katoh H, Hayashi H. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. *World J Cardiol* 2014; **6**: 585-601 [PMID: 25068019 DOI: 10.4330/wjc.v6.i7.585]

18 **Sano M**, Satoh H, Suwa K, Nobuhara M, Saitoh T, Saotome M, Urushida T, Katoh H, Shimoyama K, Suzuki D, Ogawa N, Takehara Y, Sakahara H, Hayashi H. Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis. *Heart Vessels* 2015; **30**: 779-788 [PMID: 24996373 DOI: 10.1007/s00380-014-0539-y]

19 **Richardson P**, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. *Circulation* 1996; **93**: 841-842 [PMID: 8598070 DOI: 10.1161/01.CIR.93.5.841]

20 **Okumura W**, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, Endo K, Yokoyama T, Suzuki T, Kurabayashi M. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. *J Nucl Med* 2004; **45**: 1989-1998 [PMID: 15585472]

21 **Ishimaru S**, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, Ito N, Ohira H, Ikeda D, Tamaki N, Nishimura M. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. *Eur Heart J* 2005; **26**: 1538-1543 [PMID: 15809286 DOI: 10.1093/eurheartj/ehi180]

22 **Tahara N**, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Baba K, Ishibashi M, Hayabuchi N, Narula J, Imaizumi T. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. *JACC Cardiovasc Imaging* 2010; **3**: 1219-1228 [PMID: 21163450 DOI: 10.1016/j.jcmg.2010.09.015]

23 **Alberts C**, van der Schoot JB, Groen AS. 67Ga scintigraphy as an index of disease activity in pulmonary sarcoidosis. *Eur J Nucl Med* 1981; **6**: 205-212 [PMID: 7250138 DOI: 10.1007/BF00290565]

24 **Isobe M**, Tezuka D. Isolated cardiac sarcoidosis: clinical characteristics, diagnosis and treatment. *Int J Cardiol* 2015; **182**: 132-140 [PMID: 25577749 DOI: 10.1016/j.ijcard.2014.12.056]

25 **Tezuka D**, Terashima M, Kato Y, Toriihara A, Hirasawa K, Sasaoka T, Yoshikawa S, Maejima Y, Ashikaga T, Suzuki J, Hirao K, Isobe M. Clinical characteristics of definite or suspected isolated cardiac sarcoidosis: application of cardiac magnetic resonance imaging and 18F-Fluoro-2-deoxyglucose positron-emission tomography/computerized tomography. *J Card Fail* 2015; **21**: 313-322 [PMID: 25512195 DOI: 10.1016/j.cardfail.2014.12.004]

26 **Manins V**, Habersberger J, Pfluger H, Taylor AJ. Cardiac magnetic resonance imaging in the evaluation of cardiac sarcoidosis: an Australian single-centre experience. *Intern Med J* 2009; **39**: 77-82 [PMID: 18771431 DOI: 10.1111/j.1445-5994.2008.01674.x]

27 **Watanabe E**, Kimura F, Nakajima T, Hiroe M, Kasai Y, Nagata M, Kawana M, Hagiwara N. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. *J Thorac Imaging* 2013; **28**: 60-66 [PMID: 23249970 DOI: 10.1097/RTI.0b013e3182761830]

28 **Greulich S**, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H, Schumm J, Grün S, Ong P, Wagner A, Schneider S, Nassenstein K, Gawaz M, Sechtem U, Bruder O, Mahrholdt H. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. *JACC Cardiovasc Imaging* 2013; **6**: 501-511 [PMID: 23498675 DOI: 10.1016/j.jcmg.2012.10.021]

29 **Yang Y**, Safka K, Graham JJ, Roifman I, Zia MI, Wright GA, Balter M, Dick AJ, Connelly KA. Correlation of late gadolinium enhancement MRI and quantitative T2 measurement in cardiac sarcoidosis. *J Magn Reson Imaging* 2014; **39**: 609-616 [PMID: 23720077 DOI: 10.1002/jmri.24196]

30 **Pöyhönen P**, Holmström M, Kivistö S, Hänninen H. Late gadolinium enhancement on CMR and sustained ventricular tachycardia predict severe cardiac inflammation. *Acta Cardiol* 2014; **69**: 637-647 [PMID: 25643434]

31 **Kuruvilla S**, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. *Circ Cardiovasc Imaging* 2014; **7**: 250-258 [PMID: 24363358 DOI: 10.1161/CIRCIMAGING.113.001144]

32 **Banba K**, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, Ogo KO, Nishii N, Watanabe A, Nagase S, Sakuragi S, Ohe T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. *Heart Rhythm* 2007; **4**: 1292-1299 [PMID: 17905334 DOI: 10.1016/j.hrthm.2007.06.006]

33 **Naruse Y**, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, Kuroki K, Ito Y, Yamasaki H, Igarashi M, Tada H, Nitta J, Xu D, Sato A, Aonuma K. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. *Circ Arrhythm Electrophysiol* 2014; **7**: 407-413 [PMID: 24837644 DOI: 10.1161/CIRCEP.113.000734]

34 **Murtagh G**, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, Yu Z, Addetia K, Mor-Avi V, Moss JD, Hogarth DK, Sweiss NJ, Lang RM, Patel AR. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. *Circ Cardiovasc Imaging* 2016; **9**: e003738 [PMID: 26763280 DOI: 10.1161/CIRCIMAGING.115.003738]

35 **Nadel J**, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. *Eur Heart J Cardiovasc Imaging* 2015; **16**: 634-641 [PMID: 25617029 DOI: 10.1093/ehjci/jeu294]

36 **Kumar S**, Barbhaiya C, Nagashima K, Choi EK, Epstein LM, John RM, Maytin M, Albert CM, Miller AL, Koplan BA, Michaud GF, Tedrow UB, Stevenson WG. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. *Circ Arrhythm Electrophysiol* 2015; **8**: 87-93 [PMID: 25527825 DOI: 10.1161/CIRCEP.114.002145]

37 **Nagai T**, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. *Chest* 2014; **146**: 1064-1072 [PMID: 24853830 DOI: 10.1378/chest.14-0139]

38 **Kandolin R**, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, Kokkonen J, Pelkonen M, Pietilä-Effati P, Utrianen S, Kupari M. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. *Circulation* 2015; **131**: 624-632 [PMID: 25527698 DOI: 10.1161/CIRCULATIONAHA.114.011522]

39 **Osborne MT**, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, Hainer J, Murthy VL, Skali H, Dorbala S, Di Carli MF, Blankstein R. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. *J Nucl Cardiol* 2014; **21**: 166-174 [PMID: 24307261 DOI: 10.1007/s12350-013-98286]

40 **Raphael CE**, Vassiliou V, Alpendurada F, Prasad SK, Pennell DJ, Mohiaddin RH. Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers. *Eur Heart J Cardiovasc Imaging* 2015; **pii**: jev305 [PMID: 26588986 DOI: 10.1093/ehjci/jev305]

41 **Kono T**, Ogimoto A, Saito M, Fujimoto K, Fujii A, Uetani T, Nagai T, Nishimura K, Inoue K, Suzuki J, Okura T, Kido T, Miyagawa M, Mochizuki T, Higaki J. Cardiac magnetic resonance imaging for assessment of steroid therapy in a patient with cardiac sarcoidosis and a magnetic resonance-conditional pacemaker. *Int J Cardiol* 2014; **176**: e89-e91 [PMID: 25150491 DOI: 10.1016/j.ijcard.2014.07.157]

**P-Reviewer:** Fett JD, Peteiro J, Sabate M, Teragawa H **S-Editor:** Ji FF **L-Editor: E-Editor:**

**E:\jifangfang\送修稿\2016-06-16\27306\WJC-Fig.1.tif**

**Figure 1 Non-invasive cardiac imaging in a 61-year-old male patient with cardiac involvement of systemic sarcoidosis.** LE-CMR **(A)** shows diffuse LE in the subepicardium (RV side) and subendocardium (LV side) of basal to apical ventricular septum and patchy LE in the midwall of posterior LV (white arrows). Corresponding FDG-PET **(B)** demonstrates focal uptake in basal and apical ventricular septum and posterior LV wall (black arrows). 99mTc-sestamibi SPECT **(C)** exhibits a defect only in ventricular septum (black arrows). CMR: Cardiac magnetic resonance; FDG-PET: 18F-fluorodeoxyglucose-positron emission computed tomography; LE: Late gadolinium enhancement; LV/RV: Left and right ventricles; SPECT: Single photon emission computed tomography.

E:\jifangfang\送修稿\2016-06-16\27306\WJC-Fig.2.tif

**Figure 2 Intra-left ventricles (A) and intra-mural (B) late gadolinium enhancement distribution in patients with cardiac sarcoidosis and with dilated cardiomyopathy.** A: Columns indicate prevalence of LE at each LV segment in patients with CS (black) and with DCM (gray). A: Anterior; aL: Antero-lateral; aS: Anterior septal; I: Inferior; iL: Infero-lateral wall in basal, mid and apical LV; AP: LV apex; B: Columns consist of prevalence of LE with scores 1 to 3 at different intra-mural distribution in patients with CS and with DCM. Score 4 indicates the transmural distribution. CS: Cardiac sarcoidosis; DCM: Dilated cardiomyopathy; LV: Left ventricles.

E:\jifangfang\送修稿\2016-06-16\27306\WJC-Fig.3.tif

**Figure 3 Typical late gadolinium enhancement distribution profiles.** Characteristic patterns of LE distribution in LE-MRI (A) and the cartoons (B). Striated: Striated LE distribution in midwall; Nodular: Nodular (transmural) LE distribution; Circumferential: Subepicardial LE distribution in > 50% circumferential LV wall; Subepi + Subend: Subepicardial and subendocardial LE distribution with spared midwall (white arrows); C: The prevalence of characteristic patterns of LE distribution in patients with CS and with DCM. CS: Cardiac sarcoidosis; DCM: Dilated cardiomyopathy; LE: Late gadolinium enhancement; LV/RV: Left and right ventricles; MRI: Magnetic resonance imaging.

**Table 1 Clinical cardiac findings in Diagnostic Standard and Guideline for Sarcoidosis-2015-Japanese Society of Sarcoidosis and Other Granulomatous Disorders**

(1) More than two of five major findings are satisfied

(2) One of five major findings and more than two of three minor findings are satisfied

**Major findings**

Advanced atrioventricular block (including complete atrioventricular block) or sustained ventricular tachycardia

Basal thinning of the interventricular septum or morphological ventricular abnormality (ventricular aneurysm, wall thinning of other ventricular region, wall thickening)

Impaired left ventricular contraction (LVEF < 50%) or regionally abnormal wall motion

Abnormal cardiac uptake in gallium-67 citrate scintigraphy or fluorine-18 fluorodeoxyglucose PET

Late myocardial enhancement in gadolinium enhanced magnetic resonance imaging

**Minor findings**

Non-sustained ventricular tachycardia, multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q wave in electrocardiography

Defect on myocardial perfusion scintigraphy

Endomyocardial biopsy: Interstitial fibrosis or monocyte infiltration over moderate grade

LVEF: Left ventricular ejection fraction; PET: Positron emission tomography.

**Table 2 Clinical features and magnetic resonance imaging parameters in patients with cardiac sarcoidosis and with dilated cardiomyopathy**

|  |  |  |  |
| --- | --- | --- | --- |
|  | CS | DCM | *P* values |
| Number | 14 | 30 |  |
| Sex (M/F) | M4/F10 | M23/F7 | 0.001 |
| Age (years old) | 59.8 ± 13.5 | 69.2 ± 12.6 | 0.03 |
| Syncope *n* (%) | 2 (14.3) | 6 (20.0) | 0.65 |
| Palpitation *n* (%) | 7 (50.0) | 17 (56.7) | 0.74 |
| NYHA (I/II/III/IV) | 8/5/3/1  (57.1%/35.7%/7.1%/0%) | 8/11/6/5  (26.7%/36.7%/20%/16.7%) | 0.08 |
| ECG findings |  |  |  |
| PQ duration | 188.4 ± 26.0 | 188.1 ± 40.9 | 0.91 |
| 1st/2nd AVB | 7/1 (50.0%/7.1%) | 7/0 (23.3%/0%) | 0.14 |
| QRS duration | 118.6 ± 22.9 | 128.4 ± 36.3 | 0.18 |
| Abnormal Q waves *n* (%) | 6 (42.9) | 3 (10.0) | 0.09 |
| RBBB/LBBB | 3/5 (21.4%/35.7%) | 2/15 (6.7%/50%) | 0.57 |
| VTs *n* (%) | 7 (50.0) | 15 (50.0) | 0.74 |
| Medications *n* (%) |  |  |  |
| Corticosteroids | 7 (50.0) | 0 (0) | <0.001 |
| ACEI/ARB | 9 (64.3) | 20 (66.7) | 0.73 |
| β blockers | 7 (50.0) | 23 (76.7) | 0.07 |
| AADs | 4 (28.6) | 14 (46.7) | 0.51 |
| Diuretics | 7 (50.0) | 18 (60.0) | 0.32 |
| MRI |  |  |  |
| LVEDVI (mL/m2) | 107.0 ± 45.8 | 135.5 ± 43.4 | 0.08 |
| LVESVI (mL/m2) | 74.2 ± 44.5 | 106.3 ± 42.1 | 0.04 |
| LVMI (g/m2) | 60.1 ± 24.9 | 67.1 ± 28.9 | 0.34 |
| LVEF (%) | 33.9 ± 11.0 | 22.8 ± 10.0 | 0.003 |
| LE segment number | 8.6 ± 4.6 | 5.3 ± 3.1 | 0.04 |

The categorical variables were expressed as number and percentage (%) and compared by *χ*2 test. The continuous variables were expressed as means ± SD and examined by unpaired t test. CS: Cardiac sarcoidosis; DCM: Dilated cardiomyopathy; M/F: Male/female; NYHA: New York Heart Association; ARB: Angiotensin receptor blockers; ACEI: Angiotensin converting enzyme inhibitors; AVB: Atrioventricular block; AAD: Anti-arrhythmic drugs; MRI: Magnetic resonance imaging; LVEDVI and LVESVI: Left ventricular end-diastolic and end-systolic volume indices; LVEF: LV ejection fraction; LE: Late gadolinium enhancement; L/RBBB: Left/right bundle branch blocks; LVMI: LV mass index; VT: Ventricular tachycardia.

**Table 3 Diagnostic value of characteristic late gadolinium enhancement distribution patterns to differentially diagnose cardiac sarcoidosis from dilated cardiomyopathy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| LE patterns | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| Striated | 85.7 | 3.3 | 29.3 | 33.3 |
| Nodular | 57.1 | 96.7 | 88.9 | 82.9 |
| Circumferential | 35.7 | 96.7 | 83.3 | 76.3 |
| Subepi + Subend | 50 | 96.7 | 87.5 | 80.6 |

PPV and NPV: Positive and negative predictive values; Subepi + Subend: Subepicardial and subendocardial distribution with spared midwall; LE: Late gadolinium enhancement.

**Table 4 Reports for patterns of late gadolinium enhancement distribution and clinical relevance of late gadolinium enhancement in cardiac sarcoidosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Patients** | **LE distribution** | | **Clinical relevance** |
|  |  | **Intra-cardiac** | **Intra-mural** |  |
| Smedema *et al*[8] | 12 CS | Mostly basal and lateral LV wall | Any | Diagnostic |
| Matoh*et al*[13] | 5 sCS | Mid ventricular septum | Midwall to subepicardial | Correlations between LE area and LVEDV, LVESV and LVEF |
| Ichinose *et al*[10] | 10 CS | Any, but mostly basal LV wall | Any, but mainly subepicardial | Correlations between sum of LE score and BNP, LVEF, LVEDV |
| Manis *et al*[26] | 11 CS | Ventricular septum | Patchy | Diagnostic |
| Patel *et al*[5] | 21sCS | Any, but mainly basal ventricular septum, rarely RV wall | CAD; subendo-cardial  non-CAD; mid wall, subepi-cardial, patchy | Higher rate of adverse events and cardiac death |
| Watanabe *et al*[27] | 19 CS | NA | Subepicardial, transmural | Correlations between total LE segments, and reduced LV function and duration of extra-cardiac lesions |
| Greulich *et al*[28] | 39 sCS | Any, but mainly ventricular septum (RV side) | Patchy, intramural to transmural | Higher Hazard ratio for MACE than other clinical parameters |
| Yang *et al*[29] | 6 sCS | Ventricular septum, LV free wall, papillary muscle | Patchy | Decreased T2 (inactive phase) |
| Pöyjönen *et al*[30] | 8 CS | Basal ventricular septum | Multifocal | Diagnostic |
| Tezuka *et al*[25] | 9 sCS and 4 iCS | Any, but mainly anterior ventricular septum | Any, but mainly subepicardial | No difference between sCS and iCS in LE distribution and clinical features |

BNP: Serum brain natriuretic peptide level; CAD: Coronary arterial disease type; CS: Cardiac sarcoidosis; iCS: Isolated CS; LV/RV: Left/right ventricles; LVEDV/ESV: LV end-diastolic/systolic volume; LVEF: LV ejection fractionl; MACE: Major adverse cardiac events; NA: Not available; sCS: Cardiac involvement of systemic sarcoidosis.